menu
    • menu
    [{"orgOrder":0,"company":"Talphera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Talphera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talphera \/ Undisclosed"},{"orgOrder":0,"company":"Talphera","sponsor":"U.S. Army Medical Research and Development Command","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Talphera \/ U.S. Army Medical Research and Development Command","highestDevelopmentStatusID":"10","companyTruncated":"Talphera \/ U.S. Army Medical Research and Development Command"},{"orgOrder":0,"company":"Talphera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Talphera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talphera \/ Undisclosed"},{"orgOrder":0,"company":"Talphera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Talphera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talphera \/ Undisclosed"},{"orgOrder":0,"company":"Talphera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Talphera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talphera \/ Undisclosed"},{"orgOrder":0,"company":"Talphera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talphera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talphera \/ Undisclosed"},{"orgOrder":0,"company":"Talphera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talphera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talphera \/ Undisclosed"},{"orgOrder":0,"company":"Talphera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talphera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talphera \/ Undisclosed"},{"orgOrder":0,"company":"Talphera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talphera \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Talphera \/ Undisclosed"},{"orgOrder":0,"company":"Talphera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talphera \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Talphera \/ Undisclosed"},{"orgOrder":0,"company":"Talphera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talphera \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Talphera \/ Undisclosed"},{"orgOrder":0,"company":"Talphera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talphera \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Talphera \/ Undisclosed"},{"orgOrder":0,"company":"Talphera","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Talphera","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Talphera \/ XOMA","highestDevelopmentStatusID":"15","companyTruncated":"Talphera \/ XOMA"},{"orgOrder":0,"company":"Talphera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors||Serine protease","graph1":"Nephrology","graph2":"Phase III","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talphera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talphera \/ Undisclosed"},{"orgOrder":0,"company":"Talphera","sponsor":"CorMedix","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Nephrology","graph2":"Phase III","graph3":"Talphera","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Talphera \/ CorMedix","highestDevelopmentStatusID":"10","companyTruncated":"Talphera \/ CorMedix"}]

    Find Clinical Drug Pipeline Developments & Deals by Talphera

    Menu

    Talphera

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : CorMedix

                            Deal Size : $5.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            CorMedix Announces Strategic Minority Investment in Talphera

                            Details : Talphera expects to use the proceeds of the equity financing to fund the completion of its ongoing Phase 3 registrational study for Niyad, a lyophilized formulation of nafamostat.

                            Product Name : Niyad

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 08, 2025

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : CorMedix

                            Deal Size : $5.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Talphera Enrolls First Patient in Trial for Nafamostat in Extracorporeal Circuit

                            Details : Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat mesylate and is currently being studied under an IDE as an anticoagulant for the extracorporeal circuit.

                            Product Name : Niyad

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 19, 2024

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : XOMA

                            Deal Size : $8.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

                            Details : XOMA acquired an economic interest in DSUVIA® (sufentanil sublingual tablet), an opioid agonist, indicated for use in adults, for the management of acute pain, from Talphera.

                            Product Name : Dsuvia

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            January 18, 2024

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : XOMA

                            Deal Size : $8.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Overall Performance of the Zalviso Systemâ„¢ (Sufentanil Sublingual Tablet System) 1...

                            Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acute Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 26, 2016

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg...

                            Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 25, 2016

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : U.S. Army Medical Research and Development Command

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

                            Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acute Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 19, 2015

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : U.S. Army Medical Research and Development Command

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain ...

                            Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain, Postoperative.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 05, 2015

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects

                            Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 10, 2014

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

                            Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 07, 2013

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Talphera

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

                            Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 04, 2012

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth